



Scandinavian ChemoTech Expands in Florida with Fourth Veterinary Oncology Clinic Partnership

Scandinavian ChemoTech AB today announced that its veterinary subsidiary, VQ Animal Care INC, has secured its fourth clinic partnership in Florida, further strengthening its presence in one of the most important pet care markets in the United States.

A New Option for Veterinary Oncology

VQ Animal Care Inc. today announced the fourth installation of its advanced Tumor Specific Electrochemotherapy (TSE) device, a breakthrough in veterinary oncology that enhances the effect of chemotherapy through gentle electrical pulses. This minimally invasive treatment provides veterinarians with a powerful new option for managing tumors, offering shorter recovery times, fewer side effects, and improved quality of life with reduced recurrence rates for pets. **The newly partnered oncology clinic in South Florida commented:** "We chose vetIQure™ TSE because it allows us to offer an effective and less invasive therapy to our patients. It aligns with our goal of improving treatment outcomes and giving families more options for their pets."

Florida: A Key Market for Pet Health

Florida is the **third most populous state in the U.S.**, with more than 23 million residents. It is also a highly pet-friendly state: **39.8% of households own a dog and 24.2% own a cat.** With such a large community of pet owners, expanding advanced treatment options for oncology care is a significant step forward.

Mohan Frick, CEO and Co-Inventor of TSE at VQ Animal Care Inc. said:

"TSE often reduces the total cost of care by being less invasive, causing less tissue destruction, and requiring less aftercare. For clinics, it improves efficacy while lowering side effects and reducing follow-up care demands—enhancing the overall experience for both patients and their families. We are proud to see vetIQure™ TSE growing in Florida. Cancer is one of the toughest challenges facing pets and their families, and our technology helps address it in a less disruptive, more compassionate way. Expanding our presence here means more clinics – and more pets – can benefit from this innovation."

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.